

SCALING Spatial Biology to Improve PATIENT CARE

Corporate Presentation November 2024

Disclaimers

Cautionary Note Regarding Forward-Looking Statements

This presentation includes express and implied "forward-looking statements" that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, the potential of our current and planned products and services, projected spatial biology market growth, our research and development efforts, our expectations regarding our current and potential partnerships and collaborations, revenues and earnings projections, growth prospects,, and other matters regarding our future performance, market opportunities, business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by terms such as "anticipate," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "believe," "predict," "potential," "continue," "ongoing" or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. By their nature, these statements are subject to numerous risks and uncertainties, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. For further information regarding these risks, uncertainties and other factors, you should read the "Risk Factors" section of our Quarterly Report on Form 10-Q filed for the period ended September 30, 2024 and our Annual Report on Form 10-K filed for the period ended December 31, 2023 and other documents we file with the Securities and Exchange Commission from time to time. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to update these forwardlooking statements to reflect events or circumstances after the date hereof, to reflect the occurrence of unanticipated events or for any other reason, except as required by law.

Market Industry Data

Projections, estimates, industry data and information contained in this presentation, including the Company's general expectations and market position and market opportunity, are based on information from third-party sources and management estimates. Although the Company believes that its third-party sources are reliable, the Company cannot guarantee the accuracy or completeness of its sources. The Company's estimates are derived from third-party sources, publicly available information, the Company's knowledge of its industry and assumptions based on such information and knowledge. The Company's estimates have not been verified by any independent source. All of the projections, estimates, market data and industry information used in this presentation involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. In addition, projections, estimates and assumptions relating to the Company's and its industry's future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including, but not limited to, those described above, that could cause future performance to differ materially from the Company's expressed projections, estimates and assumptions or those provided by third parties.

Akoya is Leading the Spatial Biology Revolution

Transforming Discovery to Diagnostics

Best-in-class platforms

Fastest and most robust spatial biology platforms with whole-slide and single-cell imaging



Complete end-to-end solutions

Instruments, reagents, software and services



Emerging clinical platform for next generation patient care

Expanding clinical partnerships to drive precision medicine and companion diagnostics



Established market leader with largest installed base

1,299 instruments installed worldwide*




Greatest number of high-impact publications

1,578 total publications citing Akoya's technologies*

Akoya's Spatial Biology Platforms - Transforming Tissue Analysis


Rapidly Mapping Whole Tissue at Single-cell and Subcellular Resolution



Identifying the **spatial patterns and relationships** that drive disease biology and response to therapy



Current Tissue Analysis Methods Migrating to Spatial



Current tissue analysis methods deliver no or very limited spatial information while destroying the tissue

Spatial Phenotyping:


Understanding biomarkers in tissue context while preserving the tissue



Drivers of Spatial Biology Market Growth

Translational, Clinical Research and Routine Dx Estimated to be ~70% of Market in 5 Years


- Spatial biology market expected to grow 21% annually over the next 5 years with spatial proteomics projected to surpass spatial transcriptomics in size
- Translational & clinical research expected to make up the largest market segment as spatial moves into later stage development
- Routine clinical Dx expected to be the fastest growing market segment
- Multi-plex immunofluorescence (mIF) proteomics approaches are expected to accelerate growth more than any other spatial technology



- Routine Clinical Dx
- Basic Research
- Translational & Clinical Research




Akoya's Complete End-to-End Spatial Solutions



Largest and Rapidly Growing Installed Base in the Industry

Products Across Discovery, Translational, and Clinical Markets






8

Accelerating and Market Leading Publication Volume


Akoya's Technology Consistently Featured in Leading Journals for Groundbreaking Findings





Spatial Biology Markers Predicting Response to Therapy

Predicts Response to PD-1 Blockade in Cutaneous T Cell Lymphoma (CTCL)



Non-Responders

CN10 = T_{reg} enriched

Responders

CN5 = Tumor & dendritic cells

CN8 = Tumor & CD4+ T cells

- SpatialScore derived from spatial relationship b/w PD-1+CD4+ T cells, tumor cells and immunosuppressive Tregs.
- *SpatialScore* demonstrates high correlation with response to pembrolizumab in CTCL
- PhenoCycler-Fusion high-plex data used to develop a targeted panel for larger cohort studies on the PhenoImager HT

Cellular Neighborhood (CN) Analysis Identified Localized Enrichment



ACR-368 OncoSignature Assay – a New Era of Precision Medicine

First-of-its-kind Spatial Signature CDx Assay to Identify Patients for a Targeted Oncology Agent




OncoSignature[®]



Acrivon and Akoya partnering on ongoing clinical development and future commercial use of the ACR-368 OncoSignature Assay

Acrivon granted Breakthrough Device Designation: ACR-368 OncoSignature Assay + PhenoImager HT + Akoya Software for the identification of ovarian cancer patients who may benefit from ACR-368

Acrivon granted Fast Track Designation: Investigation of ACR-368 as monotherapy based on ACR-368 OncoSignature-predicted sensitivity in patients with platinum-resistant ovarian and endometrial cancer



Akoya and Acrivon will co-develop, validate and **EXCLUSIVELY** commercialize the ACR-368 OncoSignature test



Exclusive Partnership with NeraCare in Early-stage Melanoma

ified using

nunoprint®

Immunoprint® Assay and PhenoImager HT Platform to Enable Personalized Therapy Selection

NERACARE

Stage	5-Y survival			Adjuvant therapy	
	RFS	#(4)	% of total ⁽⁵⁾		
IA	95% ⁽¹⁾	133,573	57%	Х	
IB	88%(1)	30,740	13%	Х	Iden Imm
IIA	73%(1)	18,817	8%	Х	
IIB	62% ⁽¹⁾	11,559	5%	\checkmark	
IIC	44%(1)	4,903	2%	\checkmark	
- 111	25% ^(2,3)	23,596	10%	\checkmark	
IV	n/a	12,057	5%	\checkmark	
Total		235,479	100%		

Over 235,000 new cases of melanoma diagnosed globally every year



- Currently, adjuvant therapy is only approved for stages IIB-IV resectable cutaneous melanoma (c.15-20% of patients), however, earlier-stage patients contribute a significant share of overall melanoma mortality but cannot be identified with AJCC staging
- Immunoprint® is a multiplex assay which has demonstrated robust clinical performance in identifying early-stage melanoma patients at high risk of relapse and death that could potentially benefit from on-market therapies
- Akoya and NeraCare will develop market opportunities to combine Akoya's PhenoImager HT platform and NeraCare's Immunoprint assay for therapy selection in early-stage melanoma patients

Note: Survival data in stage III refers to an untreated population / placebo arms of phase III adjuvant therapy trials

- (1) Garbe et al.: Prognosis of Pts With Melanoma Stage I and II According to AJCC v8 [...]: Implications for Adjuvant Treatment, J Clin Oncol (2022), LINK
- 2) Weber et al: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma, Cancer Immunology, Immunotherapy (2023), LINK
- (3) Garbe, [...] Eggermont: Prognosis of Patients With Stage III Melanoma According to AJCC v8, J Clin Oncol (2020), LINK
- (4) Annually diagnosed in Europe (106,310), USA & Canada (106,369), Australia & New Zealand (22,800)


(5) Patient distribution (i) according to SEER database LINK (Adjusted for unstaged pts: 5% stage IV, 11% stage III; 85% stage I&II) and (ii) further stage I&II substage distribution according to Garbe et al., J Clin Oncol (2022)



Akoya and KR Pharmtech Announce NMPA Approval for KR-HT5

Based on PhenoImager HT to Drive Next Generation Pathology Clinical Solutions in China

- KR-HT5, co-developed with Shanghai KR Pharmtech utilizing PhenoImager HT technology as its foundation, has secured premarket approval from China's National Medical Products Administration (NMPA)
- NMPA clearance allows **clinicians** to use the instrument




KR-HT5 high-throughput mIF scanning system



Akoya's Workflow – Owning the Biomarker Journey

Consistency and Flexibility Drive Platform Utilization and Pull Through Across a Continuum





PhenoCycler-Fusion 2.0 Platform


More Discoveries, Faster Than Ever — High-plex Panels for Comprehensive Coverage



AKOYA BIOSCIENCES


PhenoImager HT 2.0 Platform

The Fastest End-to-end Solution for Immuno-Oncology Spatial Signature Development





Data Analysis Ecosystem Across Akoya's Workflows




Software partnerships offer **powerful data analysis solutions** to meet the **varying requirements** of our customers



Akoya and Thermo Fisher to Deliver Leading Spatial Multiomics

Streamlined Workflow for Rapid and Whole-slide Imaging of RNA and Protein Biomarkers







MaxFuse – Multiomic Integration of Spatial and Single-cell Data

Al Driven Digital Integration of Proteomic, Transcriptomic and Epigenomic Data on Same Tissue Types







Using spatial proteomic data to maximize the value of new and historical scRNA and epigenomic data

MaxFuse enables data integration across weakly linked spatial and single-cell modalities. Nat Biotechnol (2023). S., Zhu, B., Huang, S. et al. Integration of spatial and single-cell data across modalities with weakly linked features. Nat Biotechnol (2023).



Rapidly Expanding Qualified CRO Service Provider Network

- Partnership with best-in-class CROs amplify the use of Akoya's platforms
- Qualification process ensures consistent and best practices across the network.





Akoya's New Scientific Advisory Board

Leading Experts in Innovation, Immunobiology and Immunotherapy



James Allison, Ph.D.

Chair of the Department of Immunology, MD Anderson Cancer Center

2018 Nobel Prize Winner in Physiology or Medicine





Garry Nolan, Ph.D. (Chair)

Professor in the Department of Pathology, Stanford University School of Medicine



Padmanee Sharma, M.D., Ph.D.

Professor in the Departments of Genitourinary Medical Oncology and Immunology, MD Anderson Cancer Center



Akoya's 2024 Strategic Priorities

Driving Operational Leverage and Gross Margin Improvements to Meet our Profitability Goals





Build Clinical IVD Menu

- Expand clinical trial participation leveraging our CLIA services lab and CRO partner network
- Rapidly grow CDx pipeline
- Advance clinical workflow and regulatory capabilities / readiness





22

Financial Overview



Recurring revenue model

 Recurring reagent revenue from global installed base driving projected gross margin increase



Favorable growth profile

• Expanding installed base, menu, pull through and clinical lab services

2024 Revenue Guide: \$80 – 85 Million



Path to profitability

\$39.3 million of cash, cash equivalents and marketable securities as of September 30, 2024





Catalyzing **Discovery** and Improving **Patient Care**